Home › Free Stock Grades › GLUE
Monte Rosa Therapeutics, Inc. (GLUE) Stock Grade
GLUE · Healthcare
A+
Market Cap
$1.3B
P/E Ratio
—
Revenue Growth (YoY)
+63.5%
Net Margin
-31.2%
Return on Equity
—
Dividend Yield
None
About Monte Rosa Therapeutics, Inc.'s fundamentals
Monte Rosa Therapeutics is a pre-profitability biotechnology company with a market capitalization of $1.3 billion that reported strong revenue growth of 63.5% year-over-year, though it remains unprofitable with a net margin of -31.2% and does not pay dividends. The company's financial metrics indicate it is in an early commercialization stage, burning cash as it scales operations and develops its pipeline, which is typical for biotech firms but reflects the inherent risk of companies not yet generating profits.